CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its antibody drug conjugate (ADC) SYS6023 in patients with advanced solid tumors.
SYS6023 is designed to target specific receptors on tumor surfaces, allowing it to enter tumor cells via endocytosis and release cytotoxic agents, effectively inducing tumor cell death. Pre-clinical studies have demonstrated its promising anti-tumor efficacy across multiple tumor types, positioning it as a potential breakthrough therapy in oncology.- Flcube.com
